AB Science S.A.

AB Science is a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), a new class of targeted molecules whose action is to modify signaling patways within cells. Co. targets diseases such as cancer, inflammatory diseases and central nervous system diseases, in both human and veterinary medecines. Co. has developed its own portfolio of molecules including masitinib, which has already been registered in Europe and the U.S.A. and is pursuing five phase 3 studies in human medecine, including studies in pancreatic cancer, GIST, metastatic melanoma, and studies in mastocytosis and severe persistent asthma.
  • TickerAB
  • ISINFR0010557264
  • ExchangeEuronext Paris
  • SectorPharmaceuticals & Biotechnology
  • CountryFrance

Analysts

ResearchPool Subscriptions

Get the most out of your insights

Get in touch